{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:32:02Z","timestamp":1789723922910,"version":"4.0.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest Radiol"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study investigated the potential effect of the chelating agent calcium trisodium pentetate (Ca-DTPA) on the urinary excretion of gadolinium and the subsequent elimination of gadolinium (Gd) in the brain after a single intravenous administration of either a linear (gadodiamide) or a macrocyclic (gadobutrol) Gd-based contrast agent in rats.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>Rats received either a single injection of gadodiamide or gadobutrol (1.8 mmol\/kg, each) or saline (n = 18 per group). Seven weeks after the injection, 6 animals of each group were killed before the treatment period. From the remaining 12 animals, 6 received either 3 intravenous injections of Ca-DTPA (180 \u03bcmol\/kg) or saline. Urine was collected daily for 3 days after each infusion. Gadolinium measurements by ICP-MS were performed in urine and tissue samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In animals that initially received the linear gadodiamide, Ca-DTPA infusion increased the urinary excretion of Gd by a factor of 10 (cumulative amount of 114 \u00b1 21 nmol Gd vs 10 \u00b1 4 nmol Gd after saline infusion, <jats:italic toggle=\"yes\">P<\/jats:italic> \u2264 0.0001). In contrast, animals that received the macrocyclic gadobutrol exhibited a higher spontaneous urinary excretion of Gd (33 \u00b1 12 nmol after saline infusion) and Ca-DTPA had no impact (30 \u00b1 11 nmol Gd, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.68).<\/jats:p>\n            <jats:p>The urinary excretion of Gd was associated with Gd brain content. Seven weeks after the initial Gd-based contrast agent administration, a total amount of 0.74 \u00b1 0.053 nmol Gd was quantified in the brain after administration of gadodiamide. The Gd brain burden was partially reduced at the end of the treatment period in the animals that were repeatedly infused with Ca-DTPA (0.56 \u00b1 0.13 nmol Gd, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.009) but not with saline (0.66 \u00b1 0.081 nmol, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.32). In contrast, the total amount of macrocyclic gadobutrol measured in the brain was lower (0.11 \u00b1 0.029 nmol Gd) and still spontaneously cleared during the 3-week saline infusion period (0.057 \u00b1 0.019 nmol Gd (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003). Gadolinium quantified in the brain after infusions with Ca-DTPA did not differ from saline-infused animals (0.049 \u00b1 0.014 nmol Gd).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Administration of the chelating agent Ca-DTPA 7 weeks after injection of linear gadodiamide induced relevant urinary Gd excretion. In parallel, the Gd amount in the brain tissue decreased. This indicates a dechelated pool among the chemical Gd forms present in the rat brain after linear gadodiamide administration that can be mobilized by chelation with Ca-DTPA. In contrast, Ca-DTPA did not mobilize Gd in animals that received macrocyclic gadobutrol, indicating that the Gd measured is intact gadobutrol.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rli.0000000000000522","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T19:49:19Z","timestamp":1540410559000},"page":"76-82","source":"Crossref","is-referenced-by-count":22,"title":["Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs"],"prefix":"10.1097","volume":"54","author":[{"given":"Janina","family":"Boyken","sequence":"first","affiliation":[{"name":"Institute of Physiology, Charit\u00e9 University Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frenzel","sequence":"additional","affiliation":[{"name":"MR and CT Contrast Media Research, Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lohrke","sequence":"additional","affiliation":[{"name":"MR and CT Contrast Media Research, Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Jost","sequence":"additional","affiliation":[{"name":"MR and CT Contrast Media Research, Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Sch\u00fctz","sequence":"additional","affiliation":[{"name":"MR and CT Contrast Media Research, Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubertus","family":"Pietsch","sequence":"additional","affiliation":[{"name":"MR and CT Contrast Media Research, Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230926","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-015-0275-4","article-title":"25 years of contrast-enhanced MRI: developments, current challenges and future perspectives","volume":"33","year":"2016","journal-title":"Adv Ther"},{"key":"bib2-20230926","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(17)30158-8","article-title":"Gadolinium deposition in the brain: summary of evidence and recommendations","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"key":"bib3-20230926","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.13131669","article-title":"High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material","volume":"270","year":"2014","journal-title":"Radiology"},{"key":"bib4-20230926","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial gadolinium deposition after contrast-enhanced MR imaging","volume":"275","year":"2015","journal-title":"Radiology"},{"key":"bib5-20230926","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/RLI.0000000000000072","article-title":"Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation","volume":"49","year":"2014","journal-title":"Invest Radiol"},{"key":"bib6-20230926","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1148\/radiol.2015150337","article-title":"Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent","volume":"275","year":"2015","journal-title":"Radiology"},{"key":"bib7-20230926","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/RLI.0000000000000206","article-title":"Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration","volume":"50","year":"2015","journal-title":"Invest Radiol"},{"key":"bib8-20230926","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2214\/AJR.15.15327","article-title":"Signal change in the dentate nucleus on t1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol","volume":"206","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"bib9-20230926","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1148\/radiol.14140364","article-title":"High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration","volume":"275","year":"2015","journal-title":"Radiology"},{"key":"bib10-20230926","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.2016162241","article-title":"No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents","volume":"282","year":"2017","journal-title":"Radiology"},{"key":"bib11-20230926","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/RLI.0000000000000242","article-title":"Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadolinium-based contrast agents: comparison of linear and macrocyclic agents","volume":"51","year":"2016","journal-title":"Invest Radiol"},{"key":"bib12-20230926","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/RLI.0000000000000181","article-title":"T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents","volume":"50","year":"2015","journal-title":"Invest Radiol"},{"key":"bib13-20230926","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/RLI.0b013e3181852171","article-title":"Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C","volume":"43","year":"2008","journal-title":"Invest Radiol"},{"key":"bib14-20230926","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jmri.23725","article-title":"MRI contrast agents: basic chemistry and safety","volume":"36","year":"2012","journal-title":"J Magn Reson Imaging"},{"key":"bib15-20230926","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jmri.21967","article-title":"Role of thermodynamic and kinetic parameters in gadolinium chelate stability","volume":"30","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"bib17-20230926","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/RLI.0000000000000352","article-title":"Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats","volume":"52","year":"2017","journal-title":"Invest Radiol"},{"key":"bib18-20230926","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1148\/radiol.2017162857","article-title":"Gadolinium retention in the rat brain: assessment of the amounts of insoluble gadolinium-containing species and intact gadolinium complexes after repeated administration of gadolinium-based contrast agents","volume":"285","year":"2017","journal-title":"Radiology"},{"key":"bib19-20230926","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1472-8206.2006.00447.x","article-title":"Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review","volume":"20","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"bib20-20230926","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.mri.2016.08.001","article-title":"Can gadolinium be re-chelated in vivo? Considerations from decorporation therapy","volume":"34","year":"2016","journal-title":"Magn Reson Imaging"},{"key":"bib21-20230926","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.apradiso.2005.01.005","article-title":"Treatment of accidental intakes of plutonium and americium: guidance notes","volume":"62","year":"2005","journal-title":"Appl Radiat Isot"},{"key":"bib22-20230926","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1148\/radiol.2018172746","article-title":"One-year retention of gadolinium in the brain: comparison of gadodiamide and gadoterate meglumine in a rodent model","volume":"288","year":"2018","journal-title":"Radiology"},{"key":"bib24-20230926","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3181\/00379727-91-22186","article-title":"Tissue weights of the rat. I. Normal values determined by dissection and chemical methods","volume":"91","year":"1956","journal-title":"Proc Soc Exp Biol Med"},{"key":"bib25-20230926","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1667\/RR1485.1","article-title":"Medical countermeasures against nuclear threats: radionuclide decorporation agents","volume":"170","year":"2008","journal-title":"Radiat Res"},{"key":"bib26-20230926","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/RLI.0000000000000453","article-title":"Intravenous calcium-\/zinc-diethylene triamine penta-acetic acid in patients with presumed gadolinium deposition disease: a preliminary report on 25 patients","volume":"53","year":"2018","journal-title":"Invest Radiol"},{"key":"bib27-20230926","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.mri.2016.07.016","article-title":"Gadolinium deposition disease: initial description of a disease that has been around for a while","volume":"34","year":"2016","journal-title":"Magn Reson Imaging"},{"key":"bib28-20230926","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.mri.2016.05.005","article-title":"Self-reported gadolinium toxicity: a survey of patients with chronic symptoms","volume":"34","year":"2016","journal-title":"Magn Reson Imaging"},{"key":"bib29-20230926","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1148\/radiol.2015142690","article-title":"Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy","volume":"276","year":"2015","journal-title":"Radiology"},{"key":"bib30-20230926","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/RLI.0000000000000252","article-title":"Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function","volume":"51","year":"2016","journal-title":"Invest Radiol"},{"key":"bib31-20230926","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1038\/s41598-018-22511-6","article-title":"Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents","volume":"8","year":"2018","journal-title":"Sci Rep"},{"key":"bib32-20230926","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/02841850802637808","article-title":"Effects of gadolinium contrast agents in na\u00efve and nephrectomized rats: relevance to nephrogenic systemic fibrosis","volume":"50","year":"2009","journal-title":"Acta Radiol"},{"key":"bib33-20230926","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejrad.2008.01.025","article-title":"Extracellular gadolinium contrast agents: differences in stability","volume":"66","year":"2008","journal-title":"Eur J Radiol"},{"key":"bib34-20230926","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.rpd.a006297","article-title":"Competitive binding of Pu and Am with bone mineral and novel chelating agents","volume":"105","year":"2003","journal-title":"Radiat Prot Dosimetry"},{"key":"bib35-20230926","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/RLI.0000000000000280","article-title":"Revisiting the pharmacokinetic profiles of gadolinium-based contrast agents: differences in long-term biodistribution and excretion","volume":"51","year":"2016","journal-title":"Invest Radiol"},{"key":"bib36-20230926","first-page":"322","article-title":"Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents","volume":"23","year":"2005","journal-title":"Radiat Med"},{"key":"bib37-20230926","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/RLI.0000000000000447","article-title":"Gadolinium retention, brain T1 hyperintensity, and endogenous metals: a comparative study of macrocyclic versus linear gadolinium chelates in renally sensitized rats","volume":"53","year":"2018","journal-title":"Invest Radiol"},{"key":"bib38-20230926","first-page":"758","article-title":"Convener: Michael F Tweedle","volume":"52","year":"2017","journal-title":"Invest Radiol"}],"container-title":["Investigative Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004424-201902000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T18:07:45Z","timestamp":1695751665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004424-201902000-00003"}},"subtitle":["A Comparative Study in Rats"],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rli.0000000000000522","relation":{},"ISSN":["1536-0210","0020-9996"],"issn-type":[{"value":"1536-0210","type":"electronic"},{"value":"0020-9996","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}